Sycocetam 500 mg 20 tablets
Available at Pharmaegy Pharmacy. Use as directed by your doctor.
Sycocetam Levetiracetam 500 mg 20 film coated tablets Ingredients: Levetiracetam 500 mg Indications: Sycocetam is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalisation in adults and adolescents from 16 years of age with newly diagnosed epilepsy. Sycocetam is indicated as adjunctive therapy • in the treatment of partial onset seizures with or without secondary generalisation in adults, adolescents, children and infants from 1 month of age with epilepsy. • in the treatment of myoconic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy. • in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with Idiopathic Generalised Epilepsy. Dosage and method of administration: Adults > 18 years and adolescents (12 to 17 years) 50 kg or more: The initial therapeutic dose is 500 mg levetiracetam twice daily. This dose can be started on the first day of treatment. However, a lower initial dose of 250 levetiracetam mg twice daily may be given based on physician assessment of seizure reduction versus potential side effects. This can be increased to 500 mg levetiracetam twice daily after two weeks. Depending upon the clinical response and tolerability, the daily dose can be increased up to 1,500 mg twice daily. Dose changes can be made in 250 mg or 500 mg levetiracetam twice daily increases or decreases every two to four weeks. For any doses below 500 mg refer to the doctor to determine suitable products. Method of administration: The film-coated tablets must be taken orally, swallowed with a sufficient quantity of liquid and may be taken with or without foud. Precautions: Renal impairment: The administration of levetiracetam to patients with renal impairment may require dose adjustment, In patients with severely impaired hepatic function, assessment of renal function is recommended before dose selection. Acute Kidney injury: ranging from a few days to several months. The use of levetiracetam has been very rarely associated with acute kidney injury, with a time to onset Blood cell counts: Rare cases of decreased blood cell counts (neutropenia, agranulocytosis, leucopenia, thrombocytopenia and pancytopenia) have been described in association with levetiracetam administration, generally at the beginning of the treatment Complete blood cell counts are advised in patients experiencing important weakness, pyrexia, recurrent infections or coagulation disorders. Suicide: Suicide, suicide attempt, suicidal ideation and behaviour have been reported in patients treated with anti-epileptic agents including levetiracetam. Therefore, patients should be monitored for signs of depression and/or suicidal ideation and behaviours and appropriate treatment should be considered. Abnormal and aggressive behaviours: Levetiracetam may cause psychotic symptoms and behavioural abnormalities including irritability and aggressiveness. Patients treated with levetiracetam should be monitored for developing psychiatric signs suggesting important mood and/or personality changes. Worsening of seizures: As with other types of antiepileptic drugs, levetiracetam may rarely exacerbate seizure frequency or severity. This paradoxical effect was mostly reported within the first month after levetiracetam initiation or increase of the dose, and was reversible upon drug discontinuation or dose decrease. Electrocardiogram QT interval prolongation: Rare cases of ECG QT interval prolongation have been observed during the post-marketing surveillance. Levetiracetam should be used with caution in patients with QTc-interval prolongation, in patients concomitantly treated with drugs affecting the QTc-interval, or in patients with relevant pre-existing cardiac disease or electrolyte disturbances. Paediatric population: The tablet formulation is not adapted for use in infants and children under the age of 6 years. Pregnancy and lactation: Pregnancy: Levetiracetam can be used during pregnancy, if after careful assessment it is considered clinically needed. In such case, the lowest effective dose is recommended. Breastfeeding: Levetiracetam is excreted in human breast milk. Side Effects: The most frequently reported adverse reactions were nasopharyngitis, somnolence, headache fatigue and dizziness. Very Common: Infections and infestations: Nasopharyngitis Nervous system disorders: Somnolence, headache Common: Metabolism and nutrition disorders: Anorexia Psychiatric disorders: Depression, hostility/ aggression, anxiety, Insomnia, nervousness/irritability Nervous system disorders: Convulsion, balance disorder, dizziness, lethargy, tremor Ear and Inbyrinth disorders: Vertigo Respiratory, thoracic and mediastinal disorders: Cough Gastrointestinal disorders: Abdominal pain, diarrhea, dyspepsia, vomiting, nausea Skin and subcutansons tissue disorders: Rash General disorders and administration site conditions: Asthenia/fatigue Storage Method: Store in a dry place, at a temperature not exceeding 30°C. Package: Carton box contains 2 blisters each 10 film coated tablets + insert leaflet.
